Proactive - Interviews for investors

Opyl Limited (ASX: OPL) executive director Damon Rasheed joins Proactive’s Tylah Tully to discuss the non-exclusive strategic partnership the company has entered with Alithia Life Sciences, a contract research organisation (CRO) specialising in clinical research solutions.

The collaboration aims to enhance clinical trial projects through the use of Opyl's AI-powered analytics platform, TrialKey. Under this partnership, Alithia will integrate TrialKey's AI-driven reports into its trial designs, benefiting from insights such as probability of success predictions, optimised trial strategies, and data validation. Opyl will receive over $5,000 AUD per report provided to Alithia as part of the agreement.

Both companies will collaborate on marketing activities to highlight the advantages of AI-driven solutions for clinical trials. The partnership can be terminated with 30 days’ notice, and both parties have agreed to maintain confidentiality of shared information. This collaboration reflects a shared commitment to improving clinical trial outcomes through data-backed approaches, aligning with Alithia’s focus on high-quality, efficient trial designs.

Tina Soulis, Alithia’s founder and director, expressed confidence in the partnership, while Saurabh Jain, executive chair of Opyl, highlighted its significance in supporting global clinical trials with AI-enhanced solutions.

#ProactiveInvestors #ASX #OpylLimited, #AI, #ClinicalTrials, #LifeSciences, #Partnership, #TrialKey, #Alithia, #Research, #DataDriven, #CRO, #HealthTech, #Innovation, #ClinicalResearch, #TechInMedicine, #AIinHealthcare, #Biopharma, #MedicalResearch, #ClinicalTrialDesign, #Healthcare, #PredictiveAnalytics

#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Riversgold Ltd (ASX:RGL) chairman David Lenigas joins Proactive’s Tylah Tully to discuss exploration at the company’s Northern Zone Intrusive Hosted Gold Project in Western Australia, where it has identified a gold-bearing porphyry system extending over 600 metres of strike.

The company's aircore drilling campaign has completed 30 holes, with results from the first eight confirming the presence of significant mineralisation. The remaining 22 drill results are pending.

The system, still being defined, could potentially be larger than initially expected. Riversgold chair David Lenigas noted that geological modelling supports the presence of substantial gold, with some sections extending up to 600 metres in width. The company is planning further drilling to better explore the porphyry system, which remains open in several directions.

Initial results from this round of drilling revealed gold grades of 4 metres at 1.05 g/t gold from 30 metres and 5 metres at 1.5 g/t gold from 30 metres. Previous drilling campaigns showed broader intersections, including 16 metres at 4.69 g/t gold and other significant finds.

Riversgold aims to continue exploration to gain further insight into the system before determining a mineral resource estimate. The proximity to Saturn Metals’ Apollo Hill Gold Project suggests potential for a large-scale heap leach operation.

#ProactiveInvestors #Riversgold #GoldExploration #PorphyrySystem #NorthernZoneProject #WesternAustralia #GoldMineralisation #AircoreDrilling #Kalgoorlie #MiningNews #GoldProject #ResourceEstimate #GoldGrades #GeologicalModelling #SaturnMetals #ApolloHill #HeapLeach #GoldMining #ExplorationDrilling #GoldProspecting #MineralExploration #ASX

#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Immunic Therapeutics CEO Dr Daniel Vitt joined Steve Darling from Proactive to discuss the company’s participation at the European Committee for Treatment and Research on Multiple Sclerosis conference, ECTRIMS, the world’s largest event dedicated to multiple sclerosis (MS) research. Dr. Vitt emphasized the significance of this event, where Immunic presented four research posters, including key data on vidofludimus calcium, the company’s leading compound for MS treatment.

"We have an advanced asset in multiple sclerosis in development," Dr. Vitt shared, underscoring the critical unmet medical needs in the field. He elaborated on important topics such as progression independent of relapse activity, which remains a challenging aspect of MS treatment. Immunic’s innovative research focuses on the neuroprotective, inflammatory and anti-viral properties of vidofludimus calcium, which could offer new hope to patients with progressive and relapsing forms of the disease.

In addition to showcasing their research, Dr. Vitt highlighted the networking opportunities provided by the conference, allowing Immunic to connect with key industry professionals and collaborators in the MS research community. These interactions are essential to advancing both the company’s clinical efforts and its understanding of emerging trends in the field.

#proactiveinvestors #immunictherapeutics #DanielVitt #MultipleSclerosis #MSResearch #nasdaq #imux #VidofludimusCalcium #Nurr1Activator #ProgressiveMS #RelapsingMS #Pharma #Biotech #MSDrugDevelopment. #MSResearch #Neuroprotection #ECTRIMS2024 #VidofludimusCalcium #Nurr1 #Neuroinflammation #Biotech #Pharmaceuticals #ClinicalResearch #PIRA

#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Aclara Resources Vice President Jose Palma joined Steve Darling from Proactive to share significant news regarding the Chilean government's newly launched "Industrial Strengthening Plan" for the Biobío region. Aimed at revitalizing the local economy, which has suffered from slow economic activity and inconsistent investment over the last 20 years, the plan outlines key initiatives to spur growth and development in the area.

Palma emphasized that Aclara’s Penco Module is one of the 25 major projects highlighted within this plan, signaling its importance to the region's economic future. The Industrial Strengthening Plan is designed to accelerate private investment and enhance the efficiency of institutional bodies responsible for approving such investments. The inclusion of Aclara's Penco Module underscores its potential impact, as it represents a portion of the plan's combined investment potential of US$6.8 billion.

During the operational phase of these projects, up to 5,000 jobs are expected to be created, significantly contributing to the economic recovery and development of the Biobío region. Palma expressed confidence that the Penco Module’s role in the plan will not only advance Aclara’s business objectives but also help to address the long-standing economic challenges faced by the region, paving the way for sustained growth and opportunity.

#proactiveinvestors #aclararesourcesinc #tsx #ara #mining #rareearths#AclaraResources #CarinaProject #GoiásMoU #MiningInvestment #RenewableEnergy #EnvironmentalSustainability #JobCreation #InfrastructureDevelopment #BrazilMining #SustainableMining #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

#ChileMining #EnvironmentalLicensing #CommunityEngagement #IndustrialStrengtheningPlan #GreenMining #BiobioRegion #PrivateInvestment #SustainableMining #ProactiveNews #MiningUpdates

#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Voyageur Pharmaceuticals CEO Brent Willis joined Steve Darling from Proactive to announce the successful completion of formulation work for the company’s latest product line, which includes five Health Canada-licensed products. These advanced formulations are set to raise industry standards, offering enhanced value to healthcare providers and stakeholders.

Willis also revealed the launch of two new product brands, Vision and Smooth barium contrast agents, aimed at improving versatility and performance in medical diagnostics. Classified as new drugs, these innovative products are poised to benefit from faster approval processes, significantly reducing costs and timelines compared to traditional New Drug Application (NDA) submissions.

This move marks a shift away from generics, positioning Voyageur Pharmaceuticals as a more competitive force in the market.

Voyageur has already completed several pilot test batches for its product suite and is now advancing to patient testing. The company is entering the final phase of clinical trials, where these products will be used in X-ray and Computed Tomography procedures, signaling significant progress toward full market deployment.

Additionally, the company has appointed Dr. Iryna Saranchova as its new Chief Science Officer, pending regulatory approval. Dr. Saranchova is a recognized expert in clinical research and immunology, with a distinguished career that includes roles as Honorary Professor/Lecturer at the University of British Columbia’s Faculty of Medicine and Research Fellow at the Michael Smith Laboratories and Vancouver Prostate Center. Her expertise in biomarker discovery, clinical research, and immunotherapy development will be a key asset as Voyageur accelerates its scientific initiatives.

#proactiveinvestors #voyageurpharmaceuticalsltd #tsxv #vm #vyyrf #ctscan #xray #BrentWillis, #RainCage, #Nanoscience, #MRI, #CTScan, #MedicalBreakthrough, #Fullerenes, #Vanadium, #Gadolinium, #Bismuth, #Iodine, #Radiology, #MedicalInnovation, #DrugDevelopment, #Healthcare, #ScientificBreakthrough, #Nanotechnology, #MedicalResearch, #Pharmaceuticals #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Ilan Tevet , VP of Sales and Marketing, provided an update to Steve Darling from Proactive on the company’s progress regarding its $1.05 million licensing agreement with a Tier-1 U.S.-based aerospace systems provider. Ethernity Networks, a leading supplier of data processing semiconductor technology for networking appliances, secured the deal to deliver its specialized silicon-tuned software, which will enable advanced networking functionalities on the aerospace company's unique platform.

Levi explained that the U.S. Government, as part of its review process for foreign suppliers in aerospace projects, has granted approval for Ethernity to deliver its intellectual property. This approval clears the way for the project to move into its implementation phase, triggering an immediate payment for the milestones already achieved, which account for 40% of the contract value.

Tevet further discussed the growing demand for optimized network solutions, which Ethernity plans to meet by developing an ASIC in collaboration with industry partners. This solution promises enhanced performance at a lower cost, which could drive significant growth for the company. Additionally, he touched on the opportunities arising from closing the digital divide and how Ethernity’s solutions are positioned to support broadband infrastructure developments, especially in underserved regions.

#proactiveinvestors #ethernitynetworks #aim #enet #otc #enetf

#AerospaceContract #USGovApproval #BroadbandSolutions #NetworkingTechnology #ASICDevelopment #DigitalDivide #TelecomInnovation #ProactiveInterviews

#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Giyani Metals Corp CEO Charles FitzRoy joined Steve Darling from Proactive to outline his vision for the company's future following his recent leadership transition. FitzRoy takes over from Danny Keating, bringing a wealth of experience from his previous role as Head of Corporate Development & Strategy at Giyani, where he managed relationships with original equipment manufacturers (OEMs) and off-takers. His extensive background in the lithium sector has proven valuable as the company advances its strategic objectives.

A trained geologist, FitzRoy's career spans notable roles in the mining industry, including as CEO of Bradda Head Lithium, a company he successfully took public on AIM while also leading subsequent listings on the OTCQB and TSX-V. Leveraging this experience, his focus at Giyani will be on scaling up operations, starting with a major milestone announcement—the granting of a 16-year mining license for Giyani's flagship K.Hill project.

This license is a critical development for the company, playing a key role in the ongoing Definitive Feasibility Study (DFS) for K.Hill. It will also support Giyani’s efforts to produce battery-grade manganese at its demonstration plant later this year. FitzRoy emphasized that with the mining license, environmental authorization, and secured surface rights in place, Giyani Metals has built significant momentum toward its goal of becoming a leading producer of battery-grade manganese, a key material in the rapidly growing electric vehicle and renewable energy markets.

#proactiveinvestors #giyanimetalscorp #tsxv #emm #charlesfitzroy #mining

#BatteryMetals #MiningLicense #KHillProject #ManganeseProduction #BotswanaMining #MiningNews #CharlesFitzRoy #ProactiveInvestors #MiningInvestments

#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Foresight Solar Fund Ltd fund manager Ross Driver discusses the fund's performance in the first half of 2024, highlighting how they managed to navigate challenging market conditions. Despite facing the wettest quarter in UK history and declining power prices, Driver told Proactive's Stephen Gunnion Foresight Solar delivered resilient results, falling only slightly behind revenue and EBITDA forecasts.

Driver also shared updates on the fund’s capital allocation strategy, including increasing the share buyback program to £50 million and confirming the target dividend of £0.08 per share for 2024. He discussed the ongoing sale of the Australian portfolio, totaling 170MW, expected to close by mid-2025, with proceeds planned for debt reduction.

"The first quarter was one of the wettest in recorded UK history, but despite this, cash distributions were only marginally behind forecasts," noted Driver.

Foresight Solar remains optimistic, with a growing pipeline of battery and solar projects, particularly in Europe. Driver mentioned, "We see the transition to a low carbon economy as one of the biggest investment opportunities for a generation."

Visit Proactive’s YouTube channel for more updates on Foresight Solar Fund Ltd and other investment opportunities. Don't forget to like the video, subscribe to the channel, and enable notifications for future content.

#ForesightSolar #SolarInvestment #RenewableEnergy #RossDriver #DividendUpdate #ShareBuyback #SolarPower #CleanEnergy #CapitalStrategy #AustralianDivestment #BatteryStorage #SolarGrowth #ProactiveInvestors #GreenEnergy #SustainableInvesting #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

First Phosphate's CEO, John Passalacqua and Chief Geologist Gilles Laverdiere joined Steve Darling from Proactive to discuss the results of the company's initial Mineral Resource Estimate for the Bégin-Lamarche Phosphate Project, located in Quebec. The deposit is part of the vast Lac-Saint-Jean anorthosite suite (LSJAS), recognized as the largest phosphate-mineralized anorthosite formation globally.

The estimate revealed that the Bégin-Lamarche Phosphate Deposit holds an Inferred pit-constrained Mineral Resource of 214.0 Mt at 6.01% phosphate and an Indicated pit-constrained Mineral Resource of 41.5 Mt at 6.49% phosphate. Metallurgical testing suggests an anticipated apatite concentrate grade of 40% P2O5 with an impressive 91% recovery rate.

In addition to phosphate, the deposit offers the potential for recovering two other valuable mineral products: magnetite (iron) and ilmenite (titanium). The project has significant room for expansion, as it remains open at depth.

First Phosphate is now focused on advancing the project toward a Preliminary Economic Assessment (PEA), expected later this year, which will pave the way for a Feasibility Study and potentially bring the project closer to production. This development marks a key milestone in the company’s growth and the future of phosphate production in Quebec.

#proactiveinvestors #firstphosphatecorp #phosphate #BéginLamarcheproject #CEOInterview #CompanyUpdate #StrategicGrowth #SustainableMining #GreenApproach #Geology, #Mining, #PhosphateDrilling, #ResourceEstimate, #PEA, #MountainZone, #NorthZone, #SouthZone, #DrillProgramme, #MineralExploration, #HighGradePhosphate, #GeologicalSurvey, #MiningConsultants, #3DModel, #EconomicAssessment, #ProactiveNews, #GeologicalResources, #MineralDeposit,

#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Poolbeg Pharma CEO Jeremy Skillington joined Steve Darling from Proactive to announce the company’s unaudited interim results for the first half of 2024, highlighting strong progress with its lead development candidate, POLB 001. As of 30 June 2024, the company reported a cash balance of £10.1 million, showcasing its prudent financial management and ability to support ongoing development initiatives.

Skillington emphasized that POLB 001 is on track, with robust data demonstrating its efficacy in reducing cancer immunotherapy-induced cytokine release syndrome (CRS) in an in vivo animal model. This strengthens the company's patent portfolio, with the U.S. Patent Office recently granting Poolbeg a new patent for its Immunomodulator II, covering a class of drugs, including POLB 001, aimed at treating or preventing hypercytokinemia (cytokine storm) across a range of diseases. This patent approval enhances Poolbeg’s ability to expand its intellectual property and attract potential partners.

Poolbeg Pharma is actively engaging with multiple potential partners to further develop and commercialize POLB 001. Additionally, the company signed an exclusive 12-month option agreement for tPTX, a novel topical muco-adherent treatment for oral ulcers in patients suffering from Behçet's Disease. The treatment holds significant potential, with FDA Fast Track Designation, Orphan Drug Designation, and a possible 505(b)(2) approval pathway in the U.S., indicating its promising market prospects.

Skillington emphasized Poolbeg’s commitment to advancing its pipeline while maintaining strong financial discipline, positioning the company for future growth and partnerships in the biotech sector.

#proactiveinvestors #poolbegpharma #aim #polb

#RareDiseases #JeremySkillington #GLP1Receptor #CancerImmunotherapy #PharmaNews #ClinicalTrials #FDAApproval #ProactiveInvestors#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews #RareDiseases #JeremySkillington #GLP1Receptor #CancerImmunotherapy #PharmaNews #ClinicalTrials #FDAApproval #ProactiveInvestors